Literature DB >> 33387152

Stem cell-based models and therapies: a key approach into schizophrenia treatment.

Bagher Larijani1, Peyvand Parhizkar Roudsari2, Mahdieh Hadavandkhani3, Sepideh Alavi-Moghadam3, Mostafa Rezaei-Tavirani4, Parisa Goodarzi5, Forough Azam Sayahpour6, Fereshteh Mohamadi-Jahani5, Babak Arjmand7,8.   

Abstract

Psychiatric disorders such as schizophrenia can generate distress and disability along with heavy costs on individuals and health care systems. Different genetic and environmental factors play a pivotal role in the appearance of the mentioned disorders. Since the conventional treatment options for psychiatric disorders are suboptimal, investigators are trying to find novel strategies. Herein, stem cell therapies have been recommended as novel choices. In this context, the preclinical examination of stem cell-based therapies specifically using appropriate models can facilitate passing strong filters and serious examination to ensure proper quality and safety of them as a novel treatment approach. Animal models cannot be adequately helpful to follow pathophysiological features. Nowadays, stem cell-based models, particularly induced pluripotent stem cells reflected as suitable alternative models in this field. Accordingly, the importance of stem cell-based models, especially to experiment with the regenerative medicine outcomes for schizophrenia as one of the severe typing of psychiatric disorders, is addressed here.

Entities:  

Keywords:  Disease models; Induced pluripotent stem cells; Psychiatric disorders; Regenerative medicines; Schizophrenia; Stem cell transplantation

Year:  2021        PMID: 33387152     DOI: 10.1007/s10561-020-09888-3

Source DB:  PubMed          Journal:  Cell Tissue Bank        ISSN: 1389-9333            Impact factor:   1.522


  89 in total

1.  Childhood schizophrenia.

Authors:  L BENDER
Journal:  Psychiatr Q       Date:  1953-10

Review 2.  Oxidative stress in schizophrenia: an integrated approach.

Authors:  Byron K Y Bitanihirwe; Tsung-Ung W Woo
Journal:  Neurosci Biobehav Rev       Date:  2010-10-23       Impact factor: 8.989

Review 3.  Defining psychosis: the evolution of DSM-5 schizophrenia spectrum disorders.

Authors:  Mahendra T Bhati
Journal:  Curr Psychiatry Rep       Date:  2013-11       Impact factor: 5.285

Review 4.  From "bedside" to "bench" and back: A translational approach to studying dopamine dysfunction in schizophrenia.

Authors:  Anissa Abi-Dargham
Journal:  Neurosci Biobehav Rev       Date:  2018-12-05       Impact factor: 8.989

Review 5.  Human induced pluripotent stem cells for modelling neurodevelopmental disorders.

Authors:  Karthikeyan Ardhanareeswaran; Jessica Mariani; Gianfilippo Coppola; Alexej Abyzov; Flora M Vaccarino
Journal:  Nat Rev Neurol       Date:  2017-04-18       Impact factor: 42.937

6.  Rates of 5 common antidepressant side effects among new adult and adolescent cases of depression: a retrospective US claims study.

Authors:  Heather D Anderson; Wilson D Pace; Anne M Libby; David R West; Robert J Valuck
Journal:  Clin Ther       Date:  2011-12-16       Impact factor: 3.393

7.  Age at onset in subtypes of schizophrenic disorders.

Authors:  S Beratis; J Gabriel; S Hoidas
Journal:  Schizophr Bull       Date:  1994       Impact factor: 9.306

Review 8.  Stem cell approaches in psychiatry--challenges and opportunities.

Authors:  Jens Benninghoff
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986

9.  To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial.

Authors:  Marieke J H Begemann; Ilse A Thompson; Wim Veling; Shiral S Gangadin; Chris N W Geraets; Erna van 't Hag; Sanne J Müller-Kuperus; Priscilla P Oomen; Alban E Voppel; Mark van der Gaag; Martijn J Kikkert; Jim Van Os; H Filip E Smit; Rikus H Knegtering; Sybren Wiersma; Luyken H Stouten; Harm J Gijsman; Lex Wunderink; Anton B P Staring; Selene R T Veerman; Amrita G S Mahabir; Jörg Kurkamp; Gerdina H M Pijnenborg; Natalie D Veen; Machteld Marcelis; Koen P Grootens; Gunnar Faber; Nico J van Beveren; Agaath Been; Truus van den Brink; Maarten Bak; Therese A M J van Amelsvoort; Andrea Ruissen; Christine Blanke; Karin Groen; Lieuwe de Haan; Iris E C Sommer
Journal:  Trials       Date:  2020-02-07       Impact factor: 2.279

10.  Yoga therapy for Schizophrenia.

Authors:  N Gangadhar Bangalore; Shivarama Varambally
Journal:  Int J Yoga       Date:  2012-07
View more
  2 in total

1.  An Overview of Zebrafish Modeling Methods in Drug Discovery and Development.

Authors:  Bagher Larijani; Shayesteh Kokabi Hamidpour; Akram Tayanloo-Beik; Ainaz Shahbazbadr; Hanieh Yavari; Nazli Namazi; Mahmood Biglar; Babak Arjmand
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

Review 2.  Zebrafish Modeling of Autism Spectrum Disorders, Current Status and Future Prospective.

Authors:  Akram Tayanloo-Beik; Shayesteh Kokabi Hamidpour; Mina Abedi; Hamide Shojaei; Mostafa Rezaei Tavirani; Nazli Namazi; Bagher Larijani; Babak Arjmand
Journal:  Front Psychiatry       Date:  2022-07-14       Impact factor: 5.435

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.